Parkinson s Disease Psychosis:
|
|
- Paul Allen
- 5 years ago
- Views:
Transcription
1 Parkinson s Disease Psychosis: What Mental Health Professionals Need to Know Rajeev Kumar, MD Medical Director Rocky Mountain Movement Disorders Center Huntington s Disease Society of America Center of Excellence Colorado Neurological Institute Englewood, Colorado
2 Disclosure The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). The off-label use of clozapine, quetiapine, and cholinesterase inhibitors for the treatment of Parkinson s disease psychosis will be discussed. Applicable CME staff have no relationships to disclose relating to the subject matter of this activity. This activity has been independently reviewed for balance.
3 Parkinson s Disease: A Chronic, Progressive Neurodegenerative Disorder Afflicts ~1.0 to 1.5 million people in North America Usual onset between 40 and 70 years; peak age of onset at 6th decade Affects up to 0.3% of the general population but 1% to 3% of those > 65 years Slight male predominance (3:2) 40,000 to 60,000 new cases/year Prevalence increasing as the population ages Prevalence 160/100,000 Parkinson s Foundation. Jankovic J. In: Goldman L, et al (Eds). Cecil Textbook of Medicine. 2004: Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4): Bernal-Pacheco O, et al. Neurologist. 2012;18(1):1-16. Jakel RJ, et al. Parkinson s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome. 2014;4:41-51.
4 Parkinson s Disease: A Chronic, Progressive Neurodegenerative Disorder (cont d) Causation Genetic 5% to 10% of cases monogenic 90% sporadic likely due to polygenic predisposition with significant environmental influences and there is no cure Underlying dopamine deficit occurs in the basal ganglia region of the brain Non-motor and motor symptoms are progressive and worsen over time Parkinson s Foundation. Jankovic J. In: Goldman L, et al (Eds). Cecil Textbook of Medicine. 2004: Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4): Bernal-Pacheco O, et al. Neurologist. 2012;18(1):1-16. Jakel RJ, et al. Parkinson s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome. 2014;4:41-51.
5 Parkinson s Disease PD is a progressive neurological disorder resulting predominantly from the degeneration of dopamine-producing brain cells (important for control of motor function) Parietal cortex Prefrontal premotoric cortex Striatum: N caudatus Substantia nigra: Reduction in number of dopamine-producing neurons Putamen Thalamus Striatum: Imbalance in activity of dopaminergic and cholinergic neurons PD = Parkinson s disease. Damier P, et al. Brain. 1999;122(Pt 8): Temporal cortex Substantia nigra
6 Pathology
7 Courtesy of Kapil D. Sethi, MD. Lewy Body
8 Braak Staging Hypothesis: Stages 1 and 2 Stage 1: Dorsal motor nucleus of the vagus and olfactory bulb Stage 2: Lower brainstem, including pons (medullary raphe, magnocellular portion of reticular formation, and locus coeruleus) Braak H, et al. J Neurol. 2002;249 Suppl 3:III/1-5.
9 Braak Staging Hypothesis: Stages 3 and 4 Stage 3: Amygdala, magnocellular nuclei of the basal forebrain, and pars compacta of substantia nigra Stage 4: Olfactory telencephalic cortex, temporal mesocortex Braak H, et al. J Neurol. 2002;249 Suppl 3:III/1-5.
10 Braak Staging Hypothesis: Stages 5 and 6 Stage 5: Sensory association areas, prefrontal fields of neocortex Stage 6: Primary fields of neocortex Braak H, et al. J Neurol. 2002;249 Suppl 3:III/1-5.
11 Unified Staging System for Lewy Body Disorders (USSLB) USSLB 4 Stages Stage 1: Olfactory only Stage 2A: Brainstem Stage 2B: Limbic System Stage 3: Brainstem and Limbic System Stage 4: Neocortical Includes Lewy Body and α-synuclein pathology Adler CH, et al. Mov Disord. 2016;31(8):
12 Parkinson s Disease is a Multisystem Disorder Lang AE, et al. N Engl J Med. 1998;339(15): ;
13 Parkinson s Disease: Both Motor and Non-Motor Motor Symptoms Cardinal Symptoms Resting tremor Rigidity Bradykinesia Postural instability Other Motor Symptoms Festinating gait Micrographia Masked facies Retropulsion Hypophonic speech Non-motor symptoms may have a greater impact on quality of life, but there are very few treatments approved for them. Non-Motor Symptoms Cognitive Impairment Mild cognitive impairment (MCI), Dementia Neuropsychiatric disorders Psychosis Impulse control and related disorders (ICDs) Depression Anxiety Autonomic Complications Orthostatic hypotension Constipation Urinary symptoms Sexual dysfunction Sleep Disorder Restless legs syndrome (RLS) REM behavior disorder (RBD) Excessive daytime sleepiness (EDS) Jakel RJ, et al. Parkinson s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome. 2014;4: Bernal-Pacheco O, et al. Neurologist. 2012;18(1):1-16. Martinez-Martin P, et al. Mov Disord. 2011;26(3):
14 Clinical Symptoms and Time Course of PD Progression: Pathological Progression from Prodrome to Advanced Disease Kalia LV, et al. Lancet. 2015;386(9996):
15 Parkinson s Disease Psychosis Has a Distinct Clinical Profile: NIMH Diagnostic Criteria Primary diagnosis of PD prior to the onset of psychosis A diagnosis of PD psychosis requires the presence of 1 of the following symptoms to be recurrent or continuous for at least 1 month in a person with PD: Hallucinations Delusions Illusions False sense of presence PD psychosis may occur with or without: Insight Dementia PD treatment Other potential medical and psychological causes of psychosis must be excluded Ravina B, et al. Mov Disord. 2007;22(8):
16 Both Intrinsic and Extrinsic Factors Contribute to Parkinson s Disease Psychosis Intrinsic Factors Comorbid Conditions Presence of comorbid medical or psychiatric conditions Evidence for Disease Progression PD severity PD duration Older age Cognitive impairment or dementia Evidence for Neurobiology Neurotransmitter abnormalities Neural pathways Visual processing deficits Extrinsic Factors Medications Antiparkinson medications (eg, higher levodopa dose, dopamine agonists, amantadine) Other medications (eg, anticholinergics) Environment Dim lighting Time of day Objects in environment Jakel RJ, et al. Parkinson s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome. 2014;4: Zahodne LB, et al. Drugs Aging. 2008;25(8):
17 PD Psychosis is a Common But Underrecognized Aspect of PD Likely to Become More Prevalent as Cases of PD Increase US prevalence of PD is projected to more than double in the next 2 to 3 decades > 50% of patients with PD will develop PD psychosis during the course of their disease > 2 Patients with PD do not often disclose symptoms of psychosis to their physician US-Based Projection of PD Prevalence Of the patients that reported each symptom, the percent who did not disclose: Hallucinations: 41.5% Delusions: 65.2% Kowal SL, et al. Mov Disord. 2013;28(3): Forsaa EB, et al. Arch Neurol. 2010;67(8): Chaudhuri KR, et al. Mov Disord. 2010;25(6):
18 Visual Hallucinations are the Most Common Element of PD Psychosis, Generally in Combination with Hallucinations and Delusions in Other Modalities Minor Phenomenon Hallucinations Delusions Presence hallucinations: The experience that someone is present when no one actually is Illusions: Misperceptions of real stimuli that are often visual in nature SYMPTOMS OF PD PSYCHOSIS Abnormal perceptions without a physical stimulus that can involve any sensory modality and may be simple or complex in form False, fixed, idiosyncratic beliefs that are maintained despite evidence to the contrary Visual hallucinations are the most common symptom of PD psychosis; other auditory, tactile, and olfactory hallucinations may occur in combination with the visual hallucinations or, more rarely, in isolation Delusions may encompass a variety of themes, including persecutory (someone stealing or harming the patient), jealousy, and reference Ravina B, et al. Mov Disord. 2007;22(8): Graham JM, et al. J Neurol Neurosurg Psychiatry. 1997;63(4): Llorca PM, et al. Sci Rep. 2016;6: Fénelon G, et al. Mov Disord. 2010;25(6): Fénelon G, et al. Brain. 2000;123(Pt 4): Voss T, et al. Parkinsonism Relat Disord. 2013;19(3):
19 Benign Hallucinations Do Not Remain Benign A study followed 48 PD patients with benign hallucinations (UPDRS thought disorder score of 2) who were receiving no treatment for hallucinations for at least 3 years or until a thought disorder score of 3 or 4 occurred 81% progressed to thought disorder scores of 3 or 4 78% of patients who retained a thought disorder score of 2 had their PD medications reduced to treat hallucinations Only 4% of patients were stable (ie, stable, untreated benign hallucinations over time) UPDRS = Unified Parkinson s Disease Rating Scale. Goetz CG, et al. Arch Neurol. 2006;63(5): Kaplan-Meier curve showing the time frame from study enrollment with a UPDRS thought disorder score of 2 and no treatment for hallucinations to a UPDRS thought disorder score of 3 or 4. Median time (vertical bar) for the sample of 48 participants with PD was 16 months.
20 The Course of Parkinson s Disease Psychosis Hallucinations begin Hallucinations progress Onset of delusions Nursing home placement Insight is retained While insight is retained, patients are often able to cope with symptoms without behavioral disturbances Insight is lost Caregiver burden increases Mortality at 3 years is approximately 40% for PD patients with psychosis Goetz CG, et al. Arch Neurol. 2006;63(5): Chaudhuri KR, et al. Lancet Neurol. 2006;5(3): Schrag A, et al. Parkinsonism Relat Disord. 2006;12(1): Goetz CG, et al. Neurology. 1993;43(11): Forsaa EB, et al. Neurology. 2010;75(14): Diederich NJ, et al. Mov Disord. 2003;18(7): Henderson MJ, et al. Int Rev Psychiatry. 2000;12(4):
21 The Burden of Parkinson s Disease Psychosis Caregiver burden increases as PD psychosis symptoms progress > 40% report a decline in physical health 66% report that their close relationships suffer Nearly 50% have scores indicating depression Symptoms of psychosis were identified as the reason for 24% of hospital admissions for patients with PD PD patients with hallucinations are 2.5 more likely to be admitted into a nursing home Schrag A, et al. Parkinsonism Relat Disord. 2006;12(1): Klein C, et al. J Neural Transm. 2009;116(11): Aarsland D, et al. J Am Geriatr Soc. 2000;48(8):
22 Pathophysiology of Parkinson s Disease Psychosis
23 Patients with PD Lose Serotonergic Neurons and Functioning and, as a Result, May Experience Compensatory Upregulation of 5-HT Receptors There is clear evidence of serotonergic dysfunction in PD Loss of 5-HT neurons in multiple brain pathways Reduced SERT binding Lewy body pathology in the raphe nuclei (primarily serotonergic neurons) Lewy body pathology in the cortex in later disease Patients with PD show reduced SERT binding with the greatest reductions in the forebrain in addition to the striatum Loss of raphe nuclei and certain cortical neurons may result in changes in serotonin function to compensate particularly upregulation of 5-HT 2A receptors in several brain regions Dysfunction of the serotonergic system is linked to PD psychosis Top: Normal Control Bottom: Parkinson s Disease SERT = serotonin transporter. Lang AE, et al. Lancet Neurol. 2004;3(5): Albin RL, et al. J Cereb Blood Flow Metab. 2008;28(3): Braak H, et al. Neurobiol Aging. 2003;24(2): Joutsa J, et al. J Nucl Med. 2015;56(7): Ballanger B, et al. Arch Neurol. 2010;67(4): Huot P, et al. Mov Disord. 2010;25(10):
24 Patients with Parkinson s Disease and Hallucinations Have Increased 5-HT 2A Receptor Binding Patients with PD and hallucinations have increased 5-HT 2A receptor binding in several regions of the brain, including the ventral visual pathway 5-HT 2A Receptor Binding Potential PD Patients without VH (n=7) PD Patients with VH (n=7) 5-HT 2A Binding Potential* Serotonin 5-HT 2A Binding Potential OFC IOG (R) IOG (L) FG (R) ITC DLPFC (R) DLPFC (L) PCC Insula (R) Insula (L) VH = visual hallucination; OFC = orbitofrontal cortex; IOG = inferior occipital gyrus; FG = fusiform gyrus; ITC = inferior temporal cortex; DLPFC = dorsolateral prefrontal cortex; PCC = posterior cingulate cortex; R = right; L = left. Ballanger B, et al. Arch Neurol. 2010;67(4): *The red highlighted regions indicate areas with increased 5-HT 2A receptor binding compared to patients with PD without hallucinations.
25 Increased 5-HT 2A Receptor Levels on Autopsy in PD Patients with Visual Hallucinations [ 3 H]-Ketanserin Binding (Mean ± SEM) P=.039 P=.0297 Controls All PD PD Without VH PD With VH Orbitofrontal cortex Inferolateral temporal cortex Motor cortex Striatum Substantia nigra 45.6% increase in the levels of [ 3 H]-ketanserin binding in the inferolateral temporal cortex, a critical structure in visual processing, of PD patients with VH compared to PD patients without VH. Huot P, et al. Mov Disord. 2010;25(10):
26 Reduced Raphe SERT Availability and Parkinson s Disease Symptoms Reduced raphe SERT availability is associated with the severity of resting tremor but not non-motor symptoms (fatigue, depression, and sleep disturbance) in de novo PD Other studies have linked serotoninergic dysfunction, and particularly the 5-HT 1A and 5-HT 1B receptor activity, to L-dopainduced dyskinesias Qamhawi Z, et al. Brain. 2015;138(Pt 10): Miguelez C, et al. Front Neural Circuits. 2014;8:21.
27 Serotonin Dopamine Balance Dopamine Theory: Hyperactive in mesolimbic pathway Cerebral Cortex 5-HT 2A GABA Glutamate Visual Temporal Motor Prefrontal Striatum Dorsal Ventral Raphe Substantia Nigra Ventral Tegmental Area GABA = gamma-aminobutyric acid. Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
28 Parkinson s Disease: Nigrostriatal Dopamine/D 2 Deficiency = Lewy body Cerebral Cortex 5-HT 2A GABA Glutamate Visual Temporal Motor Prefrontal Striatum Dorsal Ventral akinesia rigidity tremor Raphe Substantia Nigra Ventral Tegmental Area Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
29 3 Hypotheses of Psychosis Dopamine Theory: Hyperactive in mesolimbic pathway Serotonin Theory: 5-HT 2A receptor hyperfunction in the cortex NMDA Theory: NMDA receptor hypofunction Interconnected Pathways with one or more active in any one psychotic patient NMDA = N-methyl-D-aspartate.
30 Dopamine Theory: Hyperactive in Mesolimbic Pathway Cocaine and amphetamines stimulate D 2 receptors and cause auditory hallucinations and paranoid delusions with lack of insight Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
31 Serotonin Theory: 5-HT 2A Receptor Hyperfunction in the Cortex LSD and psilocybin simulate 5-HT 2A receptors and visual hallucinations, mystical delusions often with preserved insight Haloperidol is unable to block the visual hallucinations, but 5-HT 2A antagonists are effective Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
32 NMDA Theory: NMDA Receptor Hypofunction PCP and ketamine are NMDA receptor antagonists (in addition to amantadine) and cause visual hallucinations and paranoid delusions with lack of insight Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
33 Parkinson s Disease Psychosis: Cortical Serotonin/5-HT 2A and Mesolimbic Dopamine/D 2 Excess Superimposed Upon Nigrostriatal Dopamine/D 2 Deficiency Cerebral Cortex 5-HT 2A 5-HT 2A 5-HT 2A 5-HT 2A GABA Glutamate Striatum Dorsal Visual Temporal Motor Prefrontal akinesia rigidity tremor visual hallucinations Ventral delusions, auditory hallucinations = Lewy body Raphe Substantia Nigra Ventral Tegmental Area = Alzheimer's amyloid plaques and tangles Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
34 L-DOPA Psychosis: Dorsal to Ventral Striatal Shift and Dopamine Overdose = Lewy body Cerebral Cortex 5-HT 2A GABA Glutamate Visual Temporal Motor Prefrontal L-DOPA Raphe Striatum Dorsal Ventral Substantia Nigra akinesia rigidity tremor delusions, auditory hallucinations Ventral Tegmental Area Stahl SM. CNS Spectr. 2018;23(3): Stahl SM. CNS Spectr. 2016;21(5): Stahl SM. CNS Spectr. 2016;21(4):
35 Treatment of Parkinson s Disease Psychosis
36 Treating Psychosis in Parkinson s Disease Identify and address systemic illnesses that may trigger psychosis (eg, infection, delirium, toxic etiologies) Consider discontinuing any nonessential non-pd medications that could contribute to psychosis (eg, anticholinergics, tricyclic antidepressants, benzodiazepines, and opioids) Managing psychosis and its behavioral and emotional consequences through nonpharmacologic methods (eg, coping skills, cognitive-behavioral therapy, psychoeducation) should also be discussed with patient and family Goldman JG, et al. Curr Treat Options Neurol. 2014;16(3):281. Zahodne LB, et al. Drugs Aging. 2008;25(8):
37 Carefully Consider the Consequences to the Patient s Motor Function if Adjusting Dopaminergic Therapies to Address PD Psychosis Decreasing Dopamine replacement therapy may address psychosis, but generally worsens motor symptoms, presenting a therapeutic bind Motor Symptoms Psychosis Symptoms Reduce/ optimize drugs to reduce psychosis (expert opinion regarding order): Anticholinergics Amantadine Monoamine oxidase B inhibitors (eg, rasagiline and selegiline) Dopamine agonists (eg, pramipexole) Catechol-O-methyltransferase inhibitors (eg, entacapone) Adjust levodopa doses Goldman JG, et al. Curr Treat Options Neurol. 2014;16(3):281. Friedman JH. Expert Opin Pharmacother. 2018;19(5):
38 Antipsychotic Receptor Binding and Affinities Types of Antipsychotics Typical antipsychotics (eg, haloperidol) Share the primary pharmacologic property of D 2 receptor antagonism Atypical antipsychotics (eg, clozapine, risperidone, aripiprazole) May act via simultaneous 5-HT 2A and D 2 antagonism, partial agonist actions at 5-HT 1A receptors, partial agonist actions at D 2 receptors, or a combination of these mechanisms It is important to recognize that neither typical or atypical antipsychotics are homogenous groups Receptor Type Selected Potential Effects * Dopamine activity Antipsychotic, anti-manic, EPS, tardive dyskinesia, prolactin elevation Serotonergic activity Anxiolytic, antidepressant, increased appetite, and weight gain (?) Histaminergic activity Muscarinic activity Alpha adrenergic Anxiolytic, sedation, weight gain Cognitive blunting, dry mouth, constipation, urinary retention, blurred vision Orthostatic hypotension, drowsiness, dizziness, syncope, antidepressant * Effects may vary based upon the specific receptor affinities of each antipsychotic and dose of each antipsychotic. EPS = extrapyramidal side effects. Correll CU. Eur Psychiatry. 2010;25 Suppl 2:S12-S21. Stahl SM. Stahl s Essential Psychopharmacology. Fourth Edition. New York, NY: Cambridge University Press; 2013.
39 Atypical Antipsychotic Groupings by Relative 5-HT 2A and D 2 Receptor Affinities pimavanserin clozapine quetiapine risperidone paliperidone lurasidone aripiprazole brexpiprazole cariprazine Stahl SM. Stahl s Essential Psychopharmacology. Fourth Edition. New York, NY: Cambridge University Press; 2013.
40 Evidence-Based Treatments for Parkinson s Disease Psychosis Clozapine Efficacy Safety Practice Implications Efficacious Acceptable risk with specialized monitoring Clinically useful Olanzapine Unlikely efficacious Unacceptable risk Not useful Quetiapine Insufficient evidence Acceptable risk Investigational Prior to approval of pimavanserin. Seppi K, et al. Mov Disord. 2011;26 Suppl 3:S42-S80.
41 Current Prescribing Practices in PD Psychosis and Non-PD Dementia Psychosis Antipsychotic Prescribing With Dementia (n=793) PD Group (N=2597) Without Dementia (n=1804) N % N % Non-PD Dementia Group (N=6907) N % Test of Significance Any AP Use χ 2 =23.35, df=2, P<.001 Any Typical AP χ 2 =33.50, df=2, P<.00 High Potency χ 2 =37.00, df=2, P<.001 Any Atypical AP χ 2 =29.63, df=2, P<.001 Quetiapine χ 2 =139.35, df=2, P<.001 Risperidone χ 2 =141.88, df=2, P<.001 Aripiprazole χ 2 =21.16, df=2, P<.001 Olanzapine χ 2 =5.87, df=2, P=.053 Ziprasidone χ 2 =3.44, df=2, P=.18 Clozapine χ 2 =48.27, df=2, P<.001 Antipsychotics were prescribed in 50% of all the patients with PD and comorbid psychosis. AP = antipsychotic. Weintraub D, et al. Arch Neurol. 2011;68(7):
42 Pimavanserin is a Selective Serotonin Inverse Agonist Pimavanserin is a serotonin inverse agonist with no appreciable binding affinity to dopamine, histamine, muscarinic, or adrenergic receptors * Pimavanserin binds to 5-HT 2A receptors with a 5-fold higher selectivity over 5-HT 2C receptors 100 Agonists: Stimulate the receptor Response (%) Antagonists: Block agonists but permit basal activity US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. 0 [Drug Concentration] Inverse Agonists: Suppress basal activity
43 Pimavanserin 34 mg Reduced the Frequency and/or Severity of PD Psychosis, with Continued Improvement Over 6 Weeks* Week 0 Week 2 Week 4 Week 6 Percentage Improvement, SAPS-PD Change from Baseline Score (LSM±SE) Placebo Pimavanserin 34 mg mean point change 14% Improvement with placebo 37% Improvement with pimavanserin Primary endpoint: Change in total SAPS-PD score from baseline mean point change (P=.0014) *Mean SAPS-PD baseline score was 15.9 for pimavanserin and 14.7 for placebo. Difference in change at Week 6 between the 2 arms was 3.06 points. SAPS-PD = Scale for the Assessment of Positive Symptoms adapted for Parkinson s disease. US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Cummings J, et al. Lancet. 2014;383(9916):
44 Approximately 65% of Patients Taking Pimavanserin Experienced a 3-Point Reduction in PD Psychosis Patients (%) Worsened or No Change Point Response Point Response Point Response Change in SAPS-PD Point Response Placebo Pimavanserin 34 mg Point Response Complete Response Improvements in symptoms of psychosis were seen without worsening of motor function Hallucinations and Delusions improved 14% of patients had complete resolution of psychosis N=185. Complete response = SAPS-PD score reduced to 0 from baseline value. Patients with missing values were counted as non-responders. US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Cummings J, et al. Lancet. 2014;383(9916):
45 Pimavanserin Safety Profile: Adverse Reactions in Placebo-Controlled Studies of 6-Week Treatment Duration and Reported in 2% and > Placebo Percentage of Patients Reporting Adverse Reaction Pimavanserin 34 mg (N=202) Placebo (N=231) Peripheral edema 7% 2% Nausea 7% 4% Confusional state 6% 3% Hallucination 5% 3% Constipation 4% 3% Gait disturbance 2% < 1% Pimavanserin was not associated with increased sedation or increase in falls. *Based upon placebo-controlled 6-week trials. US Food and Drug Administration. FDA Approved Drug Products. Adverse Reactions Leading to Discontinuation of Treatment Hallucination (2% pimavanserin 34 mg vs < 1% placebo) Urinary tract infection (1% pimavanserin 34 mg vs < 1% placebo) Fatigue (1% pimavanserin 34 mg vs 0% placebo)
46 Pimavanserin Can Interact with Strong CYP3A4 Inhibitors and Inducers or with Drugs That Cause QT Interval Prolongation Strong CYP3A4 Inhibitors Concomitant use of pimavanserin with a strong CYP3A4 inhibitor increases pimavanserin exposure The recommended dose of pimavanserin when coadministered with strong CYP3A4 inhibitors (eg, ketoconazole) is 17 mg, taken orally as 1 tablet once daily Strong CYP3A4 Inducers Concomitant use of a strong CYP3A4 inducer may reduce pimavanserin exposure, resulting in a potential decrease in efficacy Patients should be monitored for reduced efficacy, and an increase in dosage may be needed if pimavanserin is used concomitantly with strong CYP3A4 inducers Concomitant Use with Drugs That Prolong QT Interval* Concomitant use of drugs that prolong the QT interval may add to the QT effects of pimavanserin and increase the risk of cardiac arrhythmias Avoid the use of pimavanserin in combination with other drugs known to prolong the QT interval *In clinical trials, pimavanserin prolonged the QT interval (mean increase ~ 5 8 msec). US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products.
47 Antipsychotic Risks in Dementia-Related Psychosis Black Box Warning Increased risk of cerebrovascular adverse events and mortality (1.7 ) secondary to cardiovascular events and infections Issued for both typical and atypical antipsychotics Also type 2 diabetes, orthostatic hypotension, sedation, dry mouth, dizziness, constipation
48 Important Safety Information for Pimavanserin WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. [Pimavanserin] is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson s disease psychosis. US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products.
49 Media Coverage of Pimavanserin
50 Mortality in Parkinson s Disease Psychosis Cox regression model adjusted to baseline age of 75 years Mortality for PD patients with (1) hallucinations with retained insight or (2) hallucinations or delusions without insight at baseline 40% at 3 years 80% at 7 years 0 1 No psychotic symptoms 2 Hallucinations with retained insight 3 4 Hallucinations or delusions without insight Forsaa EB, et al. Neurology. 2010;75(14):
51 Quetiapine Most prescribed antipsychotic for PD psychosis despite the lack of clinical efficacy data supporting its use Most movement disorders specialists and general neurologists find it to be effective in clinical practice Strong 5-HT 2A receptor antagonist and rarely worsens parkinsonism in doses of up to 100 to 200 mg/day. The usual starting dose is 25 mg qhs and this is slowly increased as needed (much lower than doses commonly used in psychiatry) Anti-histaminergic effect likely underlies the sedative effect. Psychosis in PD is commonly worse at night and sleep disruption almost universal in patients with advanced PD Improvement in sleep quality and duration may be important Reduction of caregiver stress when patient is sleeping Risk of daytime sedation and increased falls and worsening of orthostatic hypotension in this vulnerable population Ondo WG, et al. Mov Disord. 2005;20(8): Rabey JM, et al. Mov Disord. 2007;22(3): Shotbolt P, et al. Neuropsychiatr Dis Treat. 2009;5: Kurlan R, et al. Neurology. 2007;68(17):
52 Clinical Trials of Quetiapine Number of Patients Time Dose Range Average Dose Number of Dropouts Time to Dropout UPDRS BPRS Shotbolt wks mg 72.7 mg 16 Quetiapine patients dropped out faster than placebo patients No Significant Effect No Significant Effect Rabey wks 12.5 mg Starting Flexible Titration mg 26 Not Used No Significant Effect No Significant Effect Ondo wks mg Not Given 5 Not Used No Significant Effect No Significant Effect Kurlan 40 total (9 with PD psychosis) 10 wks mg 120 mg 10 Not Used No Significant Effect No Significant Effect BPRS = Brief Psychiatric Rating Scale. Ondo WG, et al. Mov Disord. 2005;20(8): Rabey JM, et al. Mov Disord. 2007;22(3): Shotbolt P, et al. Neuropsychiatr Dis Treat. 2009;5: Kurlan R, et al. Neurology. 2007;68(17):
53 Clozapine Very low D 2 affinity and high 5-HT 2A affinity which results in no worsening of parkinsonism Most potent atypical antipsychotic and commonly used in high doses in refractory schizophrenia (eg, mg/day) No worsening of parkinsonism and actually effective for parkinsonian tremor at 50 mg/day Results in dose-dependent improvement in levodopa-induced dyskinesia Highly effective in PD psychosis and highly underutilized due to need for CBC monitoring and concerns about agranulocytosis Doses in PD psychosis usually < 50 mg/day starting at 6.25 mg qhs and titrating upward Durif F, et al. Neurology. 2004;62(3): Parkinson Study Group. N Engl J Med. 1999;340(10): Pollak P, et al. J Neurol Neurosurg Psychiatry. 2004;75(5):
54 Clinical Trials of Clozapine # of Patients Time Mean Dose CGI P Value SAPS P Value BPRS P Value UPDRS P Value Positive PANSS P Value PSYCLOPS 60 4 wks 24.7 mg < Not Used French Coop 60 4 wks 35.8 mg.001 Not Used Not Used PSYCLOPS = PSYchosis and CLOzapine in the treatment of Parkinsonism; CGI = Clinical Global Impressions Scale; PANSS = Positive and Negative Syndrome Scale. Parkinson Study Group. N Engl J Med. 1999;340(10): Pollak P, et al. J Neurol Neurosurg Psychiatry. 2004;75(5):
55 Rapid Benefit and Dosing Appreciable improvement in a few days Maximum improvement reached at 3 months Mean doses 24 to 35 mg/day Doses were kept under 50 mg/day 12-week open-label extension confirmed durable efficacy in both studies Change in PANSS Score Parkinson Study Group. N Engl J Med. 1999;340(10): Pollak P, et al. J Neurol Neurosurg Psychiatry. 2004;75(5): Factor SA, et al. Mov Disord. 2001;16(1):
56 Somnolence Postural hypotension Increased salivation Confusion Seizures Rare risk of agranulocytosis Cardiomyopathy Metabolic syndrome Clozapine Adverse Effects US Food and Drug Administration. FDA Approved Drug Products.
57 Can Cholinesterase Inhibitors Improve Parkinson s Disease Psychosis? Rivastigmine is indicated for treatment of PD dementia and reduces psychosis in this population Cholinesterase inhibitors also reduce psychosis in patients with dementia with Lewy bodies The cholinergic deficit in patients with PD or PD dementia is greater than that in Alzheimer s disease It is reasonable to treat patients with PD dementia with cholinesterase inhibitors with or without psychosis. In clinical practice the antipsychotic efficacy of cholinesterase inhibitors in this population is quite mild and often inadequate when psychosis is troublesome and patients lack insight Emre M, et al. N Engl J Med. 2004;351(24): McKeith I, et al. Lancet. 2000;356(9247): Bohnen NI, et al. Arch Neurol. 2003;60(12):
58 Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson s Disease (CHEVAL) Objectives Delayed progression of minor VH to major VH without insight Motor control, psychotic symptoms, cognitive impairment, mood disorders, daytime sleepiness, adverse events and compliance, disability, caregiver burden, and care use Cost effectiveness Functional brain networks Study Design Randomized double-blind, placebo-controlled, multicenter trial with economic analysis Intervention Rivastigmine 6 mg bid or placebo Primary Endpoint Median time to progression from minor VH to major VH without insight ClinicalTrials.gov Identifier: NCT
59 Conclusions PD pathology predisposes to a variety of neuropsychiatric disorders including depression, anxiety, and dementia due to the multiple neurotransmitter systems affected PD psychosis is common and is associated with high morbidity and mortality Dopamine and serotonin abnormalities contribute to development of psychosis in PD
60 Conclusions Judiciously reducing non-pd medication that can interfere with cognition (eg, benzodiazepines) and selected other PD medications (especially anticholinergics and amantadine) may improve psychosis, but over-reduction of medication can worsen parkinsonism Antipsychotic medication targeting 5-HT 2A receptors can improve PD psychosis without compromising motor function
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by #CHAIR2016 Parkinson s Disease Psychosis: The Latest Evidence for Screening and Treatment Stuart Isaacson, MD FIU Herbert Wertheim
More informationPSYCHOSIS IN PARKINSON'S DISEASE
PSYCHOSIS IN PARKINSON'S DISEASE Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences between older antipsychotics and novel therapies for
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationSenior Care South Florida September 16, Manju T. Beier, Pharm D, CGP, FASCP
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Manju T. Beier, Pharm D, BCGP, FASCP Senior Partner, GCR LLC Adjunct Clinical Associate Professor of Pharmacy
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationParkinson s disease psychosis as a serotonin-dopamine imbalance syndrome
CNS Spectrums (2016), 21, 355 359. Cambridge University Press 2016 doi:10.1017/s1092852916000602 Parkinson s disease psychosis as a serotonin-dopamine imbalance syndrome Stephen M. Stahl ISSUE: Parkinson
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More information6/19/18. Objectives. Disclosures. Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. June 24, 2018 Objectives
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationSchizophrenia. Psychology 372 Physiological Psychology. Overview. Characterized by. Disorganized Thoughts Hallucinations Delusions Bizarre behaviors
Overview Schizophrenia Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Probably consists of more than one disorder Is the most devastating
More informationThe Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo
The Latest Research in Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo OR.. Rethinking Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationSTART THE CONVERSATION
START THE CONVERSATION ABOUT PARKINSON S DISEASE PSYCHOSIS Your patients with Parkinson s disease (PD) psychosis may be hesitant to report their symptoms LEARN MORE about how to identify the symptoms of
More informationThe antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in
Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.
More informationPsychiatric aspects of Parkinson s disease an update
Psychiatric aspects of Parkinson s disease an update Dr Chris Collins 027 2787593 chris.collins@cdhb.health.nz Disclosures: none Non-motor aspects physical Sensory anosmia, visual symptoms Speech and
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationONCE-DAILY DOSING WITH NUPLAZID
YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationParkinson s Disease Psychosis: Hallucinations Delusions and Paranoia
Parkinson s Disease Psychosis: Hallucinations Delusions and Paranoia Christopher G. Goetz, MD Professor of Neurological Sciences Professor of Pharmacology Rush University Medical Center Parkinson s Foundation
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationNew Drug Evaluation: pimavanserin tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationParkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute
Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years
More informationComprehensive Approach to DLB Management
Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures
More informationESSENTIAL PSYCHOPHARMACOLOGY, Neurobiology of Schizophrenia Carl Salzman MD Montreal
ESSENTIAL PSYCHOPHARMACOLOGY, 2011 Neurobiology of Schizophrenia Carl Salzman MD Montreal EVOLVING CONCEPTS OF SCHIZOPHRENIA Psychotic illness with delusions, hallucinations, thought disorder and deterioration;
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationPSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
PSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationCHAPTER 3. Schizophrenia and Antipsychotic Treatment
CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationAntipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1
Antipsychotics Neuroleptics/ Major Tranquilizers Hiwa K. Saaed, PhD Pharmacology & Toxicology hiwa.saaed@univsul.edu.iq 2018-2019 12/5/18 1 Learning objectives Pharmacy students should: be familiar with
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationSCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS
1 SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS OBJECTIVES 2 Know and understand: How to evaluate a person with psychotic symptoms The epidemiology and clinical characteristics of lateonset schizophrenia
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationTHIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes
THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationDelirium. A Plan to Reduce Use of Restraints. David Wensel DO, FAAHPM Medical Director Midland Care
Delirium A Plan to Reduce Use of Restraints David Wensel DO, FAAHPM Medical Director Midland Care Objectives Define delirium Describe pathophysiology of delirium Understand most common etiologies Define
More informationParkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Pari Deshmukh MD Triple board-certified psychiatrist (Boards of psychiatry, addiction medicine, integrative
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationSchizophrenia. Psychotic Disorders. Schizophrenia. Chapter 13
Schizophrenia Chapter 13 Psychotic Disorders Symptoms Alternations in perceptions, thoughts, or consciousness (delusions and hallucination) DSM-IV categories Schizophrenia Schizophreniform disorder Schizoaffective
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationNeurotransmitter Functioning In Major Depressive Disorder
Neurotransmitter Functioning In Major Depressive Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationAntidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School
Antidepressants and Sedatives David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School Depression A frequent problem, affecting up to 5% of the population Common presentations
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More information